Liang Qiao

Liang Qiao


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
HLHui Liu
Hui Liu
FGFrank Gambino
Frank Gambino
CACrystal S. Algenio
Crystal S. Algenio
CWCharles Wu
Charles Wu
YGYichen Gao
Yichen Gao
SZShaozhen Zhao
Shaozhen Zhao

1 September 1999 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
WSWei Shi
Wei Shi
PBPing Bu
Ping Bu
JLJianzhong Liu
Jianzhong Liu
APAxel Polack
Axel Polack
SFSusan Fisher
Susan Fisher
LQLiang Qiao
Liang Qiao
A human papillomavirus type 16 E7 DNA vaccine with the open reading frame encoding mutations in two zinc-binding motifs expressed a rapidly degraded E7 protein. This vaccine induced a significantly stronger E7-specific cytotoxic T-lymphocyte response and better tumor protection in mice than did a wild-type E7 DNA vaccine expressing a stable E7 protein.

1 May 2021 in Cell Reports
Verified
Journal Article
Open access
FGFrank Gambino
Frank Gambino
WTWanbo Tai
Wanbo Tai
DVDenis Voronin
Denis Voronin
YZYi Zhang
Yi Zhang
XZXiujuan Zhang
Xiujuan Zhang
LQLiang Qiao
Liang Qiao
As vaccine-induced non-neutralizing antibodies may cause antibody-dependent enhancement of Zika virus (ZIKV) infection, we test a vaccine that induces only specific cytotoxic T lymphocytes (CTLs) without specific antibodies. We construct a DNA vaccine expressing a ubiquitinated and rearranged ZIKV non-structural protein 3 (NS3). The protein is immediately degraded and processed in the proteasome for presentation via major histocompatibility complex (MHC) class I for CTL generation. We immunize Ifnar1-/- adult mice with the ubiquitin/NS3 vaccine, impregnate them, and challenge them with ZIKV. Our data show that the vaccine greatly reduces viral titers in reproductive organs and other tissues of adult mice. All mice immunized with the vaccine survived after ZIKV challenge. The vaccine remarkably reduces placenta damage and levels of pro-inflammatory cytokines, and it fully protects fetuses from damage. CD8+ CTLs are essential in protection, as demonstrated via depletion experiments. Our study provides a strategy to develop safe and effective vaccines against viral infections.

23 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
JSJuan Shi
Juan Shi
JZJian Zheng
Jian Zheng
XZXiujuan Zhang
Xiujuan Zhang
WTWanbo Tai
Wanbo Tai
RCRyan Compas
Ryan Compas
LDLanying Du
Lanying Du
SARS-CoV-2 spike–based vaccines are used to control the COVID-19 pandemic. However, emerging variants have become resistant to antibody neutralization and further mutations may lead to full resistance. We tested whether T cells alone could provide protection without antibodies. We designed a T cell–based vaccine in which SARS-CoV-2 spike sequences were rearranged and attached to ubiquitin. Immunization of mice with the vaccine induced no specific antibodies, but strong specific T cell responses. We challenged mice with SARS-CoV-2 wild-type strain or an Omicron variant after the immunization and monitored survival or viral titers in the lungs. The mice were significantly protected against death and weight loss caused by the SARS-CoV-2 wild-type strain, and the viral titers in the lungs of mice challenged with the SARS-CoV-2 wild-type strain or the Omicron variant were significantly reduced. Importantly, depletion of CD4 + or CD8 + T cells led to significant loss of the protection. Our analyses of spike protein sequences of the variants indicated that fewer than one-third presented by dominant HLA alleles were mutated and that most of the mutated epitopes were in the subunit 1 region. As the subunit 2 region is conservative, the vaccines targeting spike protein are expected to protect against future variants due to the T cell responses.

18 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XCXue Chen
Xue Chen
HLHongyang Liu
Hongyang Liu
ZWZhirong Wang
Zhirong Wang
SWShuo Wang
Shuo Wang
TZTing Zhang
Ting Zhang
XXXuemei Xu
Xuemei Xu
Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types

11 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZhenyu Zhong
Zhenyu Zhong
YZYougang Zhai
Yougang Zhai
PBPing Bu
Ping Bu
SSShivanee Shah
Shivanee Shah
LQLiang Qiao
Liang Qiao
Inducing tumour-specific adaptive immunity, such as cytotoxic T lymphocyte (CTL) response, can result in promising antitumour effect against several human malignancies, especially in combination with immune checkpoint blockade strategies. However, little is known whether activation of innate immunity can lead to direct tumoricidal effect. Here, we develop a papilloma pseudovirus-based oral immunotherapeutic approach that shows strong tumoricidal effects in the gut, resulting in an almost tripled lifespan of ApcMin/+ mice (an animal model of human intestinal tumorigenesis). Mechanistically, these pseudoviruses activate the NLRP3 and AIM2 inflammasomes, leading to caspase-1-mediated tumour regression that is dependent on neither cytotoxic T lymphocytes nor humoral immune response. Blocking caspase-1 activation abrogated the therapeutic effects of the pseudoviruses. Thus, targeting innate immune sensors in tumours by the pseudoviruses might represent a strategy to treat intestinal tumours.